ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 3000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

ישראל - עברית - Ministry of Health

sanofi israel ltd - leflunomide - טבליות מצופות פילם - leflunomide 10 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

ישראל - עברית - Ministry of Health

sanofi israel ltd - leflunomide - טבליות מצופות פילם - leflunomide 20 mg - leflunomide - leflunomide - arava is indicated in adults for the treatment of active rheumatoid arthritis (ra) : 1. to reduce signs and symptoms 2. to inhibit structural damage as evidenced by x-ray erosions and joint space narrowing 3. to imptove physical function. arava is indicated for the treatment of adult patients with active psoriatic arthritis.

ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

ישראל - עברית - Ministry of Health

teva israel ltd - loratadine - טבליה - loratadine 10 mg - other antihistamines for systemic use - relief of symptoms of allergy in seasonal allergic rhinitis, perennial allergic rhihitis, chronic urticaria.

ישראל - עברית - Ministry of Health

סיגמא בי.די - רופא - מיועד לחולים מעל גיל 18 הסובלים מאי ספיקת לב סימפטומטית עקב תפקוד סיסטולי ירוד של חדר שמאל, למרות טיפול תרופתי מתאים. the optimizer iii system indicated for use in patients greater than 18 years of age with symptomatic heart failure due to left ventricular systolic dysfunction despite appropriate medical therapy

ישראל - עברית - Ministry of Health

inspire md ltd - רופא - mguard prime coronary stent system is indicated for improving luminal diameter in vessels with reference diameter from 2.5 to 4.0 mm having lesion length <38 mm and providing embolic protection in the following cases: • symptomatic coronary artery disease due to discrete de novo or restenotic lesion in native coronary artery. • symptomatic coronary artery disease due to culprit lesion in saphenous vein graft • treatment of coronary lesion in patients undergoing primary or rescue pci for acute st-segment elevation myocardial infarction(stemi) • treatment of coronary lesion having atherothrombotic appearance in patients with non st-elevation acute coronary syndromes (unstable angina and non st-segment elevation myocardial infarction).